Thomas A. Moore, Chairman / CEO
On December 15, 2006, Thomas Moore was named our Chairman and Chief Executive Officer. He also serves as Chairman of the Board of Directors of Mayan Pigments, Inc., which has developed and patented Mayan pigment technology. Previously, from June 2002 to June 2004 Mr. Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body’s tissues. From 1996 to November 2000 he was President and Chief Executive Officer of Nelson Communications. Previously, Mr. Moore had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and group vice president of the Procter & Gamble Company.
Mark J. Rosenblum, CFO, Secretary, Senior VP
Mr. Rosenblum joined Advaxis in January 2010 as Chief Financial Officer, Senior Vice President, and Secretay. Prior to Advaxis, Mr. Rosenblum managed financial operations on behalf of an early stage publicly traded biotech headquartered in Dallas, Texas. From August 1985 through June 2003, he served in various financial leadership positions at Wellman, Inc., a chemical and recycling company. As a corporate controller for Wellman, he participated in the company’s transition from a $125 million privately held plastic recycling company into a publicly traded corporation with an excess of $400 million in revenue. In 1989, Wellman acquired the polyester assets of a former Celanese Corporation spin-off for over $550 million. Mr. Rosenbum became Vice President, Corporate Controller. Following that acquisition, the company reached almost $1 billion in revenue. In 1996, he was promoted to the position of Chief Accounting Officer, serving in that role until 2003. Mr. Rosenblum’s career has afforded him the opportunity to serve as a hands-on financial leader, participating in Wellman’s active M&A strategy, and managing the divestures for Wellman while the company navigated both the declining US textile business and the growing PET plastics packaging business. Before joining Wellman, Mark was a plant financial controller for Celanese Corp. Prior to his chemical industry experience, Mr. Rosenblum was in the public accounting profession, beginning his career with Haskins and Sells (now Deloitte and Touche) in their New York office in 1977. Mr. Rosenblum holds both a BS and Masters of Accountancy from the University of South Carolina and has been a CPA for over 30 years.
John Rothman, Ph.D., Executive VP of Science & Operations
Dr. John Rothman is currently EVP of Science & Operations at Advaxis Inc,. He was Director of Clinical Drug Development, and then Sr. Director of all of Roche’s data collection, analysis, and report writing. He was a senior scientist at Hoffmann-LaRoche working with recombinant agents provided by Genentech, where his work with interferon-α (Roferon-A) in AIDS related Kaposi’s sarcoma became the basis for the first BLA. Dr. Rothman was a member of the first clinical group to develop genetically recombinant pharmaceutical agents and test them in human disease at Schering Plough using Biogen’s α-interferon, where was the monitor for the first clinical trial in AIDS in 1984. He studied at the Department of Pharmacology at the Tulane University School of Medicine in the laboratory of Dr. Louis Ignarro (Nobel Prize; Medicine, 1998) and conducted his dissertation research at the New Orleans V.A. Hospital laboratory of Dr. Andrew Schally (Nobel Prize; Medicine, 1977). He has developed many different pharmaceutical agents in many disciplines including infectious disease, gastroenterology, neurology, oncology and virology.
Robert Petit, Ph.D., VP Clinical Operations & Medical Affairs
Dr. Robert Petit has 23 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from phase I to IV. Dr. Petit joins Advaxis from Bristol Myers Squibb where he was the U.S. Medical Strategy Lead for the Ipilimumab program, director of Medical Strategy for New Oncology Products, and director of Global Clinical Research. Prior to joining Bristol Myers-Squibb, Robert served as vice president of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a Doctorate from the Ohio State University College of Medicine and a B.S. from Indiana State University.